NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI ® (risankizumab-rzaa, 150 mg) to the U.S. Food ...
- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...
AbbVie ABBV announced that its key drug, Skyrizi (risankizumab) met all primary and secondary endpoints of a head-to-head phase III study comparing the drug against J&J’s JNJ blockbuster medicine, ...
Physicians have delivered a boost to AbbVie’s hopes of turning Skyrizi into a $17-billion-a-year drug. The 101 gastroenterologists polled by Spherix Global Insights talked up Skyrizi’s promise in ...
As AbbVie inches toward the industry’s largest-ever patent cliff—Humira's in 2023—the company's execs sound more and more enthusiastic about the immunology drugs set to inherit the blockbuster's ...
Please provide your email address to receive an email when new articles are posted on . Patients receiving maintenance risankizumab 180 mg or 360 mg achieved higher rates of clinical remission vs.
Please provide your email address to receive an email when new articles are posted on . LAS VEGAS – Patients dosed with Skyrizi for Crohn’s disease achieved clinical remission, endoscopic response and ...
SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results